ORPHA:213610
Carcinosarcoma of the corpus uteri
Also known as: Malignant mixed Müllerian tumor of the corpus uteri · Mixed Müllerian cancer of corpus uteri · Uterine carcinosarcoma
Publications
5,556
Trials
27
Interventional, condition-specific
Researchers
1,316
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Carcinosarcoma of the corpus uteri is a rare, malignant, mixed epithelial and mesenchymal tumor of the uterine body composed of high-grade carcinomatous and sarcomatous elements. It may present with vaginal bleeding, abnormal vaginal discharge, abdominal pain and/or pelvic mass, with a polypoid tumor sometimes protruding through the cervical canal. Association with Tamoxifen therapy, long-term unopposed estrogen use and previous pelvic radiotherapy has been reported.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016259
- UMLS:C1704376
- NCIT:C9180
Additional Mondo synonyms (61)
body of uterus carcinosarcoma · carcinosarcoma of corpus uteri · carcinosarcoma of the corpus uteri · carcinosarcoma of the uterine body · carcinosarcoma of the uterine corpus · carcinosarcoma of uterine body · carcinosarcoma of uterine corpus · carcinosarcoma of uterus · corpus uteri malignant mixed mesodermal tumor · corpus uteri malignant mixed mesodermal tumour · malignant mixed Mullerian tumor of the corpus uteri · malignant mixed Mullerian tumour of the corpus uteri · malignant mixed Müllerian tumor of the corpus uteri · malignant mixed Müllerian tumour of the corpus uteri · malignant mixed mesodermal neoplasm of the uterine body · malignant mixed mesodermal neoplasm of the uterine corpus · malignant mixed mesodermal neoplasm of the uterus · malignant mixed mesodermal neoplasm of uterine body · malignant mixed mesodermal neoplasm of uterine corpus · malignant mixed mesodermal neoplasm of uterus · malignant mixed mesodermal tumor of the uterine body · malignant mixed mesodermal tumor of the uterine corpus · malignant mixed mesodermal tumor of the uterus · malignant mixed mesodermal tumor of uterine body · malignant mixed mesodermal tumor of uterine corpus · malignant mixed mesodermal tumor of uterus · malignant mixed mesodermal tumour of the uterine body · malignant mixed mesodermal tumour of the uterine corpus · malignant mixed mesodermal tumour of the uterus · malignant mixed mesodermal tumour of uterine body · malignant mixed mesodermal tumour of uterine corpus · malignant mixed mesodermal tumour of uterus · mixed Mullerian cancer of corpus uteri · mixed Mullerian sarcoma of the uterus · mixed Mullerian sarcoma of uterus · mixed Müllerian cancer of corpus uteri · mixed Müllerian sarcoma of the uterus · mixed Müllerian sarcoma of uterus · uterine body carcinosarcoma · uterine body malignant mixed mesodermal neoplasm · uterine body malignant mixed mesodermal tumor · uterine body malignant mixed mesodermal tumour · uterine corpus carcinosarcoma · uterine corpus malignant mixed Mullerian neoplasm · uterine corpus malignant mixed Mullerian tumor · uterine corpus malignant mixed Mullerian tumour · uterine corpus malignant mixed Müllerian neoplasm · uterine corpus malignant mixed Müllerian tumor · uterine corpus malignant mixed Müllerian tumour · uterine corpus malignant mixed mesodermal (Mullerian) tumor · uterine corpus malignant mixed mesodermal (Mullerian) tumour · uterine corpus malignant mixed mesodermal (Müllerian) tumor · uterine corpus malignant mixed mesodermal (Müllerian) tumour · uterine corpus malignant mixed mesodermal neoplasm · uterine corpus malignant mixed mesodermal tumor · uterine corpus malignant mixed mesodermal tumour · uterine malignant mixed mesodermal neoplasm · uterine malignant mixed mesodermal tumor · uterine malignant mixed mesodermal tumour · uterine mixed Mullerian sarcoma · uterine mixed Müllerian sarcoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
5,556 matched papers (4,795 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
27 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
10
Drugs / clinical candidates · MONDO_0016259
- CARBOPLATIN·phase 2
- CISPLATIN·phase 2
- DURVALUMAB·phase 2
- IXABEPILONE·phase 2
- OLAPARIB·phase 2
- PACLITAXEL·phase 2
- PAZOPANIB HYDROCHLORIDE·phase 2
- THALIDOMIDE·phase 2
- TOPOTECAN HYDROCHLORIDE·phase 2
- GALUNISERTIB·phase 1
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
5,556
5,556 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
5,556 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
4,795 in the last 10 years · low confidence
Phrase hits: 5,556 · MeSH hits: 0
Who's working on it?
1,316
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01
- 02Li Y6 papers · 2026
Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China.
Papers in Europe PMC - 03
- 04Li L4 papers · 2025
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Papers in Europe PMC - 05Liu X4 papers · 2026
Key Laboratory of Longevity and Aging-related Diseases of Chinese Ministry of Education, Institute of Neuroscience and Guangxi Key Laboratory of Brain Science, School of Basic Medical Sciences, Guangxi Medical University, Nanning, China.
Papers in Europe PMC - 06Liu Y4 papers · 2026
Department of Clinical Pharmacy, Liaocheng Cancer Hospital, Liaocheng, P. R. China
Papers in Europe PMC - 07
- 08Sun L4 papers · 2026
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
Papers in Europe PMC - 09Wang L4 papers · 2026
Department of Pathology, The Fifth People's Hospital of Huaian, Yangzhou University Huaian, Jiangsu, China.
Papers in Europe PMC - 10Wu C4 papers · 2025
Department of Medical Laboratory, Wuhan Red Cross Hospital, Wuhan, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
27
interventional trials for this specific condition
27 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 57 trials are registered for carcinosarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
27 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 95.7th percentile).
low confidence · 95.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
27 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05902988·RECRUITING·A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Not reviewed·Conditions: Advanced Solid Tumor · High Grade Serous Adenocarcinoma of Ovary · Squamous Non-small-cell Lung Cancer · Triple Negative Breast Cancer·Matched via name phrase
- NCT05619913·RECRUITING·EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Not reviewed·Conditions: Ovarian Carcinosarcoma · Uterine Carcinosarcoma·Matched via name phrase
Broader category: carcinosarcoma
57
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT03422198·RECRUITING·Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
Not reviewed·Conditions: Endometrial Clear Cell Adenocarcinoma · Endometrial Endometrioid Adenocarcinoma · Endometrial Serous Adenocarcinoma · Stage I Uterine Corpus Cancer·Matched via name phrase
- NCT05559879·RECRUITING·Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Not reviewed·Conditions: Gynecologic Cancer · Carcinoma · Uterine Cancer · Endometrial Cancer·Matched via name phrase
- NCT06639074·RECRUITING·Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
Not reviewed·Conditions: Advanced Fallopian Tube Carcinoma · Advanced Fallopian Tube High Grade Serous Adenocarcinoma · Advanced Ovarian Carcinoma · Advanced Ovarian Carcinosarcoma·Matched via name phrase
- NCT07723235·NOT YET RECRUITING·Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial
Not reviewed·Conditions: Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8 · Endometrial Carcinoma·Matched via name phrase
- NCT04919629·RECRUITING·APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Not reviewed·Conditions: Fallopian Tube Carcinosarcoma · Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Serous Adenocarcinoma·Matched via name phrase
- NCT06638931·RECRUITING·Agnostic Therapy in Rare Solid Tumors
Not reviewed·Conditions: Urachal Cancer · Parathyroid Carcinoma · Fibrolamellar Carcinoma · Angiosarcoma·Matched via name phrase
- NCT05269381·RECRUITING·Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Not reviewed·Conditions: Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IIIA Breast Cancer AJCC v8 · Anatomic Stage IIIB Breast Cancer AJCC v8 · Anatomic Stage IIIC Breast Cancer AJCC v8·Matched via name phrase
- NCT05646316·RECRUITING·Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Not reviewed·Conditions: Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8·Matched via name phrase
- NCT05920798·RECRUITING·Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Not reviewed·Conditions: Fallopian Tube Carcinosarcoma · Primary Peritoneal Carcinosarcoma · Recurrent Fallopian Tube Carcinoma · Recurrent Fallopian Tube Clear Cell Adenocarcinoma·Matched via name phrase
- NCT05542407·RECRUITING·ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Not reviewed·Conditions: Endometrial Cancer · Metastasis · Endometrioid Endometrial Cancer · Carcinosarcoma·Matched via name phrase
- NCT03651206·RECRUITING·Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Not reviewed·Conditions: Ovarian Carcinosarcoma · Endometrial Carcinosarcoma·Matched via name phrase
- NCT06483048·RECRUITING·MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Not reviewed·Conditions: Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma · Recurrent Fallopian Tube Carcinoma·Matched via name phrase
- NCT05256225·RECRUITING·Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Not reviewed·Conditions: Endometrial Carcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Dedifferentiated Carcinoma · Endometrial Endometrioid Adenocarcinoma·Matched via name phrase
- NCT05500391·RECRUITING·Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Not reviewed·Conditions: Stage I Testicular Seminoma · Stage I Testicular Nonseminomatous Germ Cell Tumor · Gastrointestinal Stromal Tumors · Ovarian Germ Cell Tumor·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Carcinosarcoma of the corpus uteri — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Carcinosarcoma of the corpus uteri" OR "Carcinosarcoma of corpus uteri" OR "Malignant mixed Müllerian tumor of the corpus uteri" OR "Malignant mixed Müllerian tumor of corpus uteri" OR "Mixed Müllerian cancer of corpus uteri" OR "Mixed Müllerian cancer of the corpus uteri" OR "Uterine carcinosarcoma" OR "body of uterus carcinosarcoma" OR "body of the uterus carcinosarcoma" OR "carcinosarcoma of the uterine body" OR "carcinosarcoma of uterine body" OR "carcinosarcoma of the uterine corpus" OR "carcinosarcoma of uterine corpus" OR "carcinosarcoma of uterus" OR "carcinosarcoma of the uterus" OR "corpus uteri malignant mixed mesodermal tumor" OR "corpus uteri malignant mixed mesodermal tumour" OR "malignant mixed Mullerian tumor of the corpus uteri" OR "malignant mixed Mullerian tumor of corpus uteri" OR "malignant mixed Mullerian tumour of the corpus uteri" OR "malignant mixed Mullerian tumour of corpus uteri" OR "malignant mixed Müllerian tumour of the corpus uteri" OR "malignant mixed Müllerian tumour of corpus uteri" OR "malignant mixed mesodermal neoplasm of the uterine body" OR "malignant mixed mesodermal neoplasm of uterine body" OR "malignant mixed mesodermal neoplasm of the uterine corpus" OR "malignant mixed mesodermal neoplasm of uterine corpus" OR "malignant mixed mesodermal neoplasm of the uterus" OR "malignant mixed mesodermal neoplasm of uterus" OR "malignant mixed mesodermal tumor of the uterine body" OR "malignant mixed mesodermal tumor of uterine body" OR "malignant mixed mesodermal tumor of the uterine corpus" OR "malignant mixed mesodermal tumor of uterine corpus" OR "malignant mixed mesodermal tumor of the uterus" OR "malignant mixed mesodermal tumor of uterus" OR "malignant mixed mesodermal tumour of the uterine body" OR "malignant mixed mesodermal tumour of uterine body" OR "malignant mixed mesodermal tumour of the uterine corpus" OR "malignant mixed mesodermal tumour of uterine corpus" OR "malignant mixed mesodermal tumour of the uterus"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Carcinosarcoma of the corpus uteri" OR "Carcinosarcoma of corpus uteri" OR "Malignant mixed Müllerian tumor of the corpus uteri" OR "Malignant mixed Müllerian tumor of corpus uteri" OR "Mixed Müllerian cancer of corpus uteri" OR "Mixed Müllerian cancer of the corpus uteri" OR "Uterine carcinosarcoma" OR "body of uterus carcinosarcoma" OR "body of the uterus carcinosarcoma" OR "carcinosarcoma of the uterine body" OR "carcinosarcoma of uterine body" OR "carcinosarcoma of the uterine corpus" OR "carcinosarcoma of uterine corpus" OR "carcinosarcoma of uterus" OR "carcinosarcoma of the uterus" OR "corpus uteri malignant mixed mesodermal tumor" OR "corpus uteri malignant mixed mesodermal tumour" OR "malignant mixed Mullerian tumor of the corpus uteri" OR "malignant mixed Mullerian tumor of corpus uteri" OR "malignant mixed Mullerian tumour of the corpus uteri" OR "malignant mixed Mullerian tumour of corpus uteri" OR "malignant mixed Müllerian tumour of the corpus uteri" OR "malignant mixed Müllerian tumour of corpus uteri" OR "malignant mixed mesodermal neoplasm of the uterine body" OR "malignant mixed mesodermal neoplasm of uterine body" OR "malignant mixed mesodermal neoplasm of the uterine corpus" OR "malignant mixed mesodermal neoplasm of uterine corpus" OR "malignant mixed mesodermal neoplasm of the uterus" OR "malignant mixed mesodermal neoplasm of uterus" OR "malignant mixed mesodermal tumor of the uterine body" OR "malignant mixed mesodermal tumor of uterine body" OR "malignant mixed mesodermal tumor of the uterine corpus" OR "malignant mixed mesodermal tumor of uterine corpus" OR "malignant mixed mesodermal tumor of the uterus" OR "malignant mixed mesodermal tumor of uterus" OR "malignant mixed mesodermal tumour of the uterine body" OR "malignant mixed mesodermal tumour of uterine body" OR "malignant mixed mesodermal tumour of the uterine corpus" OR "malignant mixed mesodermal tumour of uterine corpus" OR "malignant mixed mesodermal tumour of the uterus"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 27 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"carcinosarcoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: malignant mixed mesodermal tumour of uterus; mixed Mullerian cancer of corpus uteri; mixed Mullerian cancer of the corpus uteri; mixed Mullerian sarcoma of the uterus; mixed Mullerian sarcoma of uterus; mixed Müllerian sarcoma of the uterus; mixed Müllerian sarcoma of uterus; uterine body carcinosarcoma; uterine body malignant mixed mesodermal neoplasm; uterine body malignant mixed mesodermal tumor; uterine body malignant mixed mesodermal tumour; uterine corpus carcinosarcoma; uterine corpus malignant mixed Mullerian neoplasm; uterine corpus malignant mixed Mullerian tumor; uterine corpus malignant mixed Mullerian tumour; uterine corpus malignant mixed Müllerian neoplasm; uterine corpus malignant mixed Müllerian tumor; uterine corpus malignant mixed Müllerian tumour; uterine corpus malignant mixed mesodermal (Mullerian) tumor; uterine corpus malignant mixed mesodermal (Mullerian) tumour; uterine corpus malignant mixed mesodermal (Müllerian) tumor; uterine corpus malignant mixed mesodermal (Müllerian) tumour; uterine corpus malignant mixed mesodermal neoplasm; uterine corpus malignant mixed mesodermal tumor; uterine corpus malignant mixed mesodermal tumour; uterine malignant mixed mesodermal neoplasm; uterine malignant mixed mesodermal tumor; uterine malignant mixed mesodermal tumour; uterine mixed Mullerian sarcoma; uterine mixed Müllerian sarcoma
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (5556) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T09:35:03.115Z